62 results
8-K
GOSS
Gossamer Bio Inc
4 Mar 24
Other Events
4:02pm
from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance … is now closed. The letter was pursuant to a previous letter received on October 19, 2023 from Nasdaq the Listing Qualifications Department of Nasdaq
8-K
GOSS
Gossamer Bio Inc
20 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm
Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), notifying the Company that, for the 30 consecutive business day period between September
8-K
EX-10.1
trr5i q42gag1
20 Jul 23
Gossamer Bio Announces $212 Million Private Placement Financing
4:01pm
PRE 14A
d5bk mkslp8pr3440777
17 Apr 23
Preliminary proxy
4:01pm
8-K
EX-10.1
vr4evo31lw0gw9
13 Jul 22
Gossamer Bio Announces $120 million Private Placement Financing
8:45am
8-K
EX-99.1
r4bawq
20 Apr 21
Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer
4:44pm
8-K
EX-99.2
7ds5njizq5uc17h
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am